Insider filing
Traded Apr 9 · filed the same day
Derivative exercise or conversion — not an open-market buy.
Ask OQRO reads the filings behind this page and answers in plain words, with a link to each source.
Ask OQRO is part of OQRO Pro. Everything else on OQRO is free.
Only to see which pages are hard to use, so we can fix them. Nothing is used for ads, and what you type stays hidden (Microsoft Clarity, PostHog). Privacy Policy
Traded Mar 11, 2026 · Filed Mar 11, 2026
The CFO of Edwards Lifesciences sold $673K of Edwards Lifesciences shares. The filing says it was made under a pre-arranged trading plan.
Written from the filing's own figures. OQRO describes what was reported and never tells you what to buy or sell.
open market sale
Code S — open-market or private sale
~$673,228
Shares × reported transaction price
29 days after results of Feb 10, 2026, 43 days before results of Apr 23, 2026
Results dates are the company's own 8-K (Item 2.02). Many companies only let insiders trade in a window after results
Closed at $85.09 on Mar 11, 2026, within 3% of its 52-week high, after a 2% rise over the previous 30 trading days
52-week range $67.07 (Apr 8, 2025) to $87.18 (Mar 2, 2026), 90% of the way up, from 251 adjusted closes. 30 trading days earlier: $83.60 on Jan 27, 2026. Describes the past only, not a forecast
RSI 56, 6% above its 200-day average, 3% above its 50-day average, 2% below the 52-week high, 20-day volatility 33% a year, against the S&P 500: +13 points over 1 month, +2 points over 3 months, +3 points over 6 months
From the adjusted closes up to Mar 11, 2026. RSI: Wilder's 14-day relative strength index (0 to 100). Averages: the last 50 and 200 closes. Volatility: standard deviation of the last 20 daily returns, annualised. S&P 500: the stock's move minus SPY's between the same dates (21, 63 and 126 trading days). Describes the past only, not a forecast
Footnote references a pre-arranged trading plan (Rule 10b5-1)
Only flagged when a footnote says so; never inferred
A securities lawsuit naming the company as a defendant was filed on Oct 14, 2024 in the U.S. District Court, C.D. California. A filing is an allegation, not a finding.
Dhimant Patel v. Edwards Lifesciences Corporation, docket 8:24-cv-02221, via CourtListener (court records). Nature of suit 850, company named as first defendant
| After | Stock | S&P 500 | Difference |
|---|---|---|---|
| 7 days | −2.5% | −0.9% | −1.6% |
| 30 days | −7.7% | +3.0% | −10.7% |
| 90 days | +1.6% | +8.9% | −7.3% |
| 180 days | +2.5% | +15.0% | −12.5% |
Past results only. Not a forecast.
Insider filing
Traded Apr 9 · filed the same day
Derivative exercise or conversion — not an open-market buy.
Scott B. Ullem (CVP, Chief Financial Officer) sold ~$376K of Edwards Lifesciences
Planned saleScott B. Ullem (CVP, Chief Financial Officer) sold ~$664K of Edwards Lifesciences
Planned saleEvery dated public record OQRO holds about the company from 60 days before to 120 days after, oldest first. It shows what was going on; none of it is a stated reason for the trade.